Abstract:Apatinib is a tyrosine kinase inhibitor which selectively inhibits VEGFR-2 and also represents mild inhibition to PDGFR, c-Kit and c-src. It is an orally bioavailable, small molecule agent which is thought to inhibit angiogenesis and tumor cell proliferation. Previous clinical trials have demonstrated its obvious antitumor activity in various cancer type. Thus we designed this phase II, open-label, single-armed, prospective study (NCT02515435) to investigate the efficacy and safety of apatinib for heavily treated, advanced non-squamous NSCLC patients who are not applicable to current standardized therapy or other clinical trials. We prospectively enrolled 40 patients with previously heavily treated advanced non-squamous NSCLC. All patients received apatinib with a dose of 500mg, q.d., p.o. Efficiency was evaluated initially 4 weeks later and then every 8 weeks until disease progression, death, or unacceptable toxicity. The primary end point of this study was overall response rate (ORR). The secondary end points were progression-free survival (PFS), overall survival (OS). Forty patients were enrolled in the study with a median age of 61. 15% of patients received apatinib as second-line therapy, 40% of patients received apatinib as third-line therapy, and 60% as forth-line to twelfth-line therapy. Nine patients were found with activated EGFR mutation. Among all the enrolled patients, 38 patients had clinical evaluation and the other 2 received treatment of apatinib less than one month. Within 33 patients who had available image efficiency, 6 were identified as PR,17 SD and 10 PD, no CR was observed. The ORR was 18.18 %, the DCR was 69.69%. The ORR for patients with EGFR mutation positive and negative were 25% and 16% separately. The median PFS was 3.22 months (95% CI, 2.20-4.17 months). Among them, 6 patients received the treatment of apatinib more than five months. The 6-month OS rate was 76.98% (95% CI, 61.68%-92.27%), the 12-month OS rate was 57.48% (95% CI, 28.75%-86.20%). Common treatment-related adverse events were proteinuria (25%), hypertension (17.5%), and hand-foot-skin reaction (HFSR)(27.5%). Severe adverse events included grade 3 hypertension (5%), HFSR (5%), and thrombocytopenia (5%), no grade 4 or 5 adverse events were observed. No un-expected adverse events were found. Apatinib as a monotherapy had a promising overall response together with an acceptable side effect in patients with previously heavily treated advanced non-squamous NSCLC. A phase III study comparing apatinib monotherapy with placebo as 3rd/4th setting in advanced non-squamous NSCLC is ongoing to further evaluated the efficacy of apatinib (NCT02332512).

Effects of Apatinib on the "Stemness" of Non-Small-Cell Lung Cancer Cells In Vivo and Its Related Mechanisms

Apatinib triggers autophagic and apoptotic cell death via VEGFR2/STAT3/PD-L1 and ROS/Nrf2/p62 signaling in lung cancer

Effect of Apatinib on Invasion and Migration of Lung Cancer Cells and Its Mechanism

Apatinib inhibits the growth of small cell lung cancer via a mechanism mediated by VEGF, PI3K/Akt and Ki‐67/CD31

Apatinib Inhibits Proliferation and Induces Apoptosis of Acute Myeloid Leukemia Stem/progenitor Like Cell Line (kg1α cells) and Its Mechanism

Apatinib Combined with Local Irradiation Leads to Systemic Tumor Control Via Reversal of Immunosuppressive Tumor Microenvironment in Lung Cancer.

The inhibitory effect of apatinib on different small cell lung cancer cells and in lung cancer‐bearing mice and patients

The Efficacy and Safety of Apatinib in the Treatment of Advanced Non-Small Cell Lung Cancer: A Retrospective Trial

P3.02c-025 Safety and Efficacy of Apatinib in Patients with Previously Heavily Treated Advanced Non-Squamous Non-Small-Cell Lung Cancer

Wnt/β-catenin Signaling Pathway in Lung Cancer Stem Cells is a Potential Target for the Development of Novel Anticancer Drugs.

Combined Treatment of Apatinib with Docetaxel in Non-Small-Cell Lung Cancer Mice and Its Material Basis of Pharmacokinetics.

Apatinib Suppresses Gastric Cancer Stem Cells Properties by Inhibiting the Sonic Hedgehog Pathway

Apatinib repressed the invasion and metastasis of hepatoceilular carcinoma cells by inhibiting epithelial-mesenchymal transformation

Therapeutic Potential of Apatinib Against Colorectal Cancer by Inhibiting VEGFR2-Mediated Angiogenesis and -Catenin Signaling

Efficacy of Apatinib in treatment of advanced lung cancer

Apatinib to Enhance Antitumor Activity of Gefitinib in Non-Small Cell Lung Cancer.

Apatinib Inhibits Pancreatic Cancer Growth, Migration and Invasion Through the PI3K/AKT and ERK1/2/MAPK Pathways.

Apatinib Inhibits Proliferation and Induces Apoptosis of Acute Myeloid Leukemia Stem/Progenitor Like Cell Line(kg1α Cells) by Inhibition PI3K/AKT Signal Pathway

Effects of Combined Inhibition of STAT3 and VEGFR2 Pathways on the Radiosensitivity of Non-Small-cell Lung Cancer Cells

Effect of STAT-3-mediated non-dependent VEGFR-2 pathway on radiosensitivity of non-small cell lung cancer cells

Efficacy, Safety and Predictive Indicators of Apatinib after Multilines Treatment in Advanced Nonsquamous Nonsmall Cell Lung Cancer: Apatinib Treatment in Nonsquamous NSCLC.